Φορτώνει......
Evaluation of CpG Island Methylator Phenotype as a biomarker in colorectal cancer treated with adjuvant oxaliplatin
BACKGROUND: The CpG island methylator phenotype (CIMP) is a promising biomarker for irinotecan/5-fluorouracil/leucovorin chemotherapy in stage III colon cancer. In the present study, we evaluated whether CIMP is a prognostic biomarker for standard-of-care oxaliplatin-based adjuvant therapy. MATERIAL...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Clin Colorectal Cancer |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
2015
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4864501/ https://ncbi.nlm.nih.gov/pubmed/26702772 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clcc.2015.10.005 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|